One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
SHL Medical is a pioneering leader in self-injection solutions, such as autoinjectors. Driven by our purpose of “enabling patients’ independence”, we partner with leading pharma and biotech companies to develop self-injection systems and digital solutions that enhance patients’ treatment experience and quality of life.
Our customers benefit from our proven track record and scalable, global manufacturing excellence, with locations across three continents and headquarters in Switzerland. By focusing on innovation, we challenge the status quo and shape the future of state-of-the-art drug delivery.
Main Competitive Advantages: Brand Name,International Approvals/Standards,Experienced R&D Staff,Delivery Term,Production Capacity,Large Product Line,Contract Manufacturing (CRO,CMO),Buyers' Specifications Accepted,Small Orders Accepted,Reputation,Quality Service
Other Competitive Advantages: - Support of 50+ combination products to market launch
- Top 25 majority of pharma/biotech companies in partnership with SHL
- Over 33% compound annual shipment growth rate (CAGR) 2018-2024
- More than 142 million SHL autoinjectors reached patients worldwide in 2024
Patents and Copyrights:
Business Type: Service Provider,Manufacturer
R&D capacity: OEM
Annual Turnover(USD):
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia
Other Competitive Advantages: - Support of 50+ combination products to market launch
- Top 25 majority of pharma/biotech companies in partnership with SHL
- Over 33% compound annual shipment growth rate (CAGR) 2018-2024
- More than 142 million SHL autoinjectors reached patients worldwide in 2024
Audited Supplier
Pharma Sources Insight January 2025
